Current management of polycythemia vera.
Over a century has elapsed since the first description of polycythemia vera (PV), and current treatment recommendations are primarily based on the results of clinical trials that were performed in the late 1960s and early 1970s. Continued identification and appropriate utilization of PV-specific biologic parameters may allow substantial modification of early diagnostic criteria. New cytoreductive treatment agents are increasingly being used without any evidence of superiority over conventional therapy. The role of aspirin is being readdressed by an ongoing controlled study. Transformation of PV into either myelofibrosis with myeloid metaplasia or acute leukemia remains a major complication that may not be influenced by current therapy.
Tefferi
Ayalew
A
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced / Q000473:pathology; D019468:Disease Management; D006801:Humans; D007951:Leukemia, Myeloid / Q000209:etiology / Q000473:pathology; D011087:Polycythemia Vera / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents